TW201605859A - 作為酪蛋白激酶１δ／ε抑制劑之新穎經取代之吡唑并－哌 - Google Patents

作為酪蛋白激酶１δ／ε抑制劑之新穎經取代之吡唑并－哌 Download PDF

Info

Publication number
TW201605859A
TW201605859A TW103139448A TW103139448A TW201605859A TW 201605859 A TW201605859 A TW 201605859A TW 103139448 A TW103139448 A TW 103139448A TW 103139448 A TW103139448 A TW 103139448A TW 201605859 A TW201605859 A TW 201605859A
Authority
TW
Taiwan
Prior art keywords
substituted
independently selected
alkyl
occurrence
group
Prior art date
Application number
TW103139448A
Other languages
English (en)
Chinese (zh)
Inventor
阿潘德 維拉帕斯
奇坦 帕達美克 達尼
佩尹 劉
馬克Ｄ 瓦特曼
布萊德利Ｃ 皮爾斯
艾瑞卡 雅羅喬
畢瑞斯渥 達斯古塔
加拉斯 蘇瑞德瑞 奈爾
沙克希 庫馬瑞 賈納卡瑞曼
錢德雷席克爾 瑞迪 瑞加瑞迪
麥圖 馬立卡吉那 萊歐
奧爾 莫希 塞爾凡 蘇比哈 卡路琵雅
班迪瑞迪 索巴 瑞迪
波里奇拉 那嘉拉許彌
拉傑許 歐卡德斯 寶拉
席帕 荷利哈提 馬赫斯瓦倫帕
庫瑪拉佛 沙瓦庫瑪
迪巴卡 穆立克
拉米許 西斯特拉
Original Assignee
必治妥美雅史谷比公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 必治妥美雅史谷比公司 filed Critical 必治妥美雅史谷比公司
Publication of TW201605859A publication Critical patent/TW201605859A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
TW103139448A 2013-11-14 2014-11-13 作為酪蛋白激酶１δ／ε抑制劑之新穎經取代之吡唑并－哌 TW201605859A (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361904116P 2013-11-14 2013-11-14

Publications (1)

Publication Number Publication Date
TW201605859A true TW201605859A (zh) 2016-02-16

Family

ID=51952052

Family Applications (1)

Application Number Title Priority Date Filing Date
TW103139448A TW201605859A (zh) 2013-11-14 2014-11-13 作為酪蛋白激酶１δ／ε抑制劑之新穎經取代之吡唑并－哌

Country Status (9)

Country Link
US (3) US9598423B2 (enExample)
EP (2) EP3068785B1 (enExample)
JP (2) JP6494624B2 (enExample)
CN (2) CN105916856B (enExample)
AR (1) AR098414A1 (enExample)
ES (2) ES2718218T3 (enExample)
TW (1) TW201605859A (enExample)
UY (1) UY35834A (enExample)
WO (2) WO2015073767A1 (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR098414A1 (es) 2013-11-14 2016-05-26 Bristol Myers Squibb Co PIPERAZINAS DE PIRAZOLO SUSTITUIDO COMO INHIBIDORES DE CASEÍNA QUINASA 1 d/e
WO2015129821A1 (ja) 2014-02-27 2015-09-03 国立大学法人東京大学 オートタキシン阻害活性を有する縮合ピラゾール誘導体
MA41338B1 (fr) * 2015-01-16 2019-07-31 Hoffmann La Roche Composés de pyrazine pour le traitement de maladies infectieuses
EP3426245B1 (en) 2016-03-07 2022-12-14 Enanta Pharmaceuticals, Inc. Hepatitis b antiviral agents
WO2017156071A1 (en) 2016-03-09 2017-09-14 Blade Therapeutics, Inc. Cyclic keto-amide compounds as calpain modulators and methods of production and use thereof
CN109153682B (zh) * 2016-05-20 2021-05-25 豪夫迈·罗氏有限公司 用于治疗感染性疾病的具有氧、硫和氮连接基的新的吡嗪化合物
EP3481835A4 (en) 2016-07-05 2020-02-26 Blade Therapeutics, Inc. CALPAIN MODULATORS AND THEIR THERAPEUTIC USES
CN109476668B (zh) * 2016-07-14 2022-03-22 豪夫迈·罗氏有限公司 用于治疗感染性疾病的6,7-二氢-4H-吡唑并[1,5-a]吡嗪和6,7-二氢-4H-三唑并[1,5-a]吡嗪化合物
WO2018064119A1 (en) * 2016-09-28 2018-04-05 Blade Therapeutics, Inc. Calpain modulators and therapeutic uses thereof
TWI782056B (zh) * 2017-07-14 2022-11-01 日商鹽野義製藥股份有限公司 具有ｍｇａｔ２抑制活性的縮合環衍生物
JP2020528062A (ja) * 2017-07-27 2020-09-17 江蘇恒瑞医薬股▲ふん▼有限公司 ピペラジンヘテロアリール誘導体、その製造方法、およびその医薬での使用
AU2018326474B2 (en) 2017-08-28 2024-07-25 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
TWI846350B (zh) 2017-09-15 2024-06-21 美商佛瑪治療公司 作為ＣＢＰ／ｐ３００抑制劑之四氫－咪唑並喹啉化合物
AU2018360577A1 (en) 2017-11-01 2020-06-18 Bristol-Myers Squibb Company Bridged bicyclic compounds as farnesoid X receptor modulators
WO2019143902A2 (en) 2018-01-22 2019-07-25 Enanta Pharmaceuticals, Inc. Substituted heterocycles as antiviral agents
US10729688B2 (en) * 2018-03-29 2020-08-04 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
US11591328B2 (en) * 2018-06-01 2023-02-28 Xiamen Biotime Biotechnology Co., Ltd. Highly active CSF1R inhibitor compound
KR102805503B1 (ko) 2018-06-29 2025-05-09 포르마 세라퓨틱스 인크. Creb 결합 단백질(cbp)의 저해
AR116474A1 (es) 2018-09-21 2021-05-12 Enanta Pharm Inc DERIVADOS DEL ÁCIDO 6,7-DIHIDRO-2H-BENZOFURO[2,3-a]QUINOLIZIN-3-CARBOXÍLICO COMO AGENTES ANTIVIRALES PARA EL TRATAMIENTO O PREVENCIÓN DE UNA INFECCIÓN POR HBV
BR112021009854A2 (pt) 2018-11-21 2021-08-17 Enanta Pharmaceuticals, Inc. heterociclos funcionalizados como agentes antivirais
EP3909583A4 (en) 2019-01-11 2022-08-17 Shionogi & Co., Ltd DIHYDROPYRAZOLOPYRAZINONE DERIVATIVES WITH MGAT2 INHIBITORY ACTIVITY
TW202043233A (zh) * 2019-01-25 2020-12-01 大陸商江蘇恒瑞醫藥股份有限公司 1,2,3-三氮唑并[1,5-a]吡類衍生物的晶型及其製備方法
CN111484498B (zh) * 2019-01-25 2021-05-14 江苏恒瑞医药股份有限公司 咪唑并[1,5-a]吡嗪类化合物的晶型及其制备方法
CN111484497B (zh) * 2019-01-25 2021-07-02 江苏恒瑞医药股份有限公司 咪唑并[1,5-a]吡嗪类衍生物的可药用盐、晶型及其制备方法
CA3128946A1 (en) 2019-02-07 2020-08-13 Bayer Aktiengesellschaft 3-amino-2-[2-(acylamino)pyridin-4-yl]-1,5,6,7-tetrahydro-4h-pyrrolo[3,2-c]pyridin-4-one as csnk1 inhibitors
WO2020190791A1 (en) 2019-03-15 2020-09-24 Forma Therapeutics, Inc. Inhibiting cyclic amp-responsive element-binding protein (creb)
WO2020247444A1 (en) 2019-06-03 2020-12-10 Enanta Pharmaceuticals, Inc, Hepatitis b antiviral agents
WO2020247561A1 (en) 2019-06-04 2020-12-10 Enanta Pharmaceuticals, Inc, Hepatitis b antiviral agents
WO2020247575A1 (en) 2019-06-04 2020-12-10 Enanta Pharmaceuticals, Inc. Hepatitis b antiviral agents
US11738019B2 (en) 2019-07-11 2023-08-29 Enanta Pharmaceuticals, Inc. Substituted heterocycles as antiviral agents
WO2021055425A2 (en) 2019-09-17 2021-03-25 Enanta Pharmaceuticals, Inc. Functionalized heterocycles as antiviral agents
US11802125B2 (en) 2020-03-16 2023-10-31 Enanta Pharmaceuticals, Inc. Functionalized heterocyclic compounds as antiviral agents
CN114057745A (zh) * 2020-07-29 2022-02-18 江苏恒瑞医药股份有限公司 一种三氮唑并[1,5-a]吡嗪制备方法及其应用
AU2021342792A1 (en) * 2020-09-17 2023-06-01 Janssen Pharmaceutica Nv Casein kinase 1 delta modulators
US11801243B2 (en) 2020-09-23 2023-10-31 Forma Therapeutics, Inc. Bromodomain inhibitors for androgen receptor-driven cancers
US11795168B2 (en) 2020-09-23 2023-10-24 Forma Therapeutics, Inc. Inhibiting cyclic amp-responsive element-binding protein (CREB) binding protein (CBP)
WO2022166778A1 (zh) * 2021-02-04 2022-08-11 江苏恒瑞医药股份有限公司 一种衣壳蛋白抑制剂的药物组合物及其制备方法
EP4469457A1 (en) * 2022-01-27 2024-12-04 The Broad Institute Inc. Substituted heterocyclic csnk1 inhibitors
KR20250022711A (ko) * 2022-06-13 2025-02-17 시오노기 앤드 컴파니, 리미티드 다이하이드로피리딘온 유도체 또는 그 용매화물의 결정

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04002243A (es) * 2001-09-19 2004-06-29 Aventis Pharma Sa Compuestos quimicos.
ATE428711T1 (de) * 2003-12-11 2009-05-15 Aventis Pharma Inc Substituierte 1h-pyrroloä3,2-b, 3,2-c und 2,3- cüpyridin-2-carbonsäureamide und verwandte analoga als inhibitoren von caseinkinase-i- epsilon
US20050222171A1 (en) * 2004-01-22 2005-10-06 Guido Bold Organic compounds
US20070155738A1 (en) 2005-05-20 2007-07-05 Alantos Pharmaceuticals, Inc. Heterobicyclic metalloprotease inhibitors
CN101417999A (zh) 2007-10-25 2009-04-29 上海恒瑞医药有限公司 哌嗪类衍生物,其制备方法及其在医药上的应用
EP2085398A1 (en) 2008-02-01 2009-08-05 Merz Pharma GmbH & Co. KGaA Pyrazolopyrimidines, a process for their preparation and their use as medicine
JP2012503623A (ja) 2008-09-24 2012-02-09 ビーエーエスエフ ソシエタス・ヨーロピア 無脊椎動物系害虫防除用ピラゾール化合物
US8703778B2 (en) 2008-09-26 2014-04-22 Intellikine Llc Heterocyclic kinase inhibitors
WO2010059836A1 (en) 2008-11-20 2010-05-27 Decode Genetics Ehf Substituted aza-bridged bicyclics for cardiovascular and cns disease
TW201035102A (en) 2009-03-04 2010-10-01 Gruenethal Gmbh Sulfonylated tetrahydroazolopyrazines and their use as medicinal products
FR2960876B1 (fr) * 2010-06-03 2012-07-27 Sanofi Aventis Derives de 3,4-dihydropyrrolo[1,2-a]pyrazine-2,8(1h)-dicarboxamide leur preparation et leur application en therapeutique.
CN102372716A (zh) 2010-08-09 2012-03-14 江苏恒瑞医药股份有限公司 酞嗪酮类衍生物、其制备方法及其在医药上的应用
US9226929B2 (en) 2011-03-02 2016-01-05 Bayer Intellectual Property Gmbh Pharmaceutically active disubstituted triazine derivatives
AR098414A1 (es) 2013-11-14 2016-05-26 Bristol Myers Squibb Co PIPERAZINAS DE PIRAZOLO SUSTITUIDO COMO INHIBIDORES DE CASEÍNA QUINASA 1 d/e

Also Published As

Publication number Publication date
ES2718218T3 (es) 2019-06-28
US20160122358A1 (en) 2016-05-05
UY35834A (es) 2015-05-29
ES2744636T3 (es) 2020-02-25
JP6494624B2 (ja) 2019-04-03
EP3068785A1 (en) 2016-09-21
US9598423B2 (en) 2017-03-21
JP2016537369A (ja) 2016-12-01
CN105916855B (zh) 2019-03-15
WO2015073763A1 (en) 2015-05-21
US20150133428A1 (en) 2015-05-14
CN105916856B (zh) 2018-09-25
EP3068784A1 (en) 2016-09-21
CN105916855A (zh) 2016-08-31
AR098414A1 (es) 2016-05-26
WO2015073767A1 (en) 2015-05-21
EP3068784B1 (en) 2019-02-20
JP6494622B2 (ja) 2019-04-03
EP3068785B1 (en) 2019-06-26
US9273058B2 (en) 2016-03-01
JP2016537366A (ja) 2016-12-01
CN105916856A (zh) 2016-08-31
US20160311824A1 (en) 2016-10-27

Similar Documents

Publication Publication Date Title
TW201605859A (zh) 作為酪蛋白激酶１δ／ε抑制劑之新穎經取代之吡唑并－哌
CN101305011B (zh) 吡啶衍生物及其在治疗精神障碍中的用途
AU2018312326B2 (en) Heterocyclic compound and use thereof
JP7471348B2 (ja) ブルトン型チロシンキナーゼの阻害剤及びその使用方法
TWI730937B (zh) Ｇｐｒ６ 的四氫吡啶並吡調節劑
CN104470925B (zh) 作为激酶抑制剂的咪唑并三嗪甲腈
EP4578853A2 (en) Heterocyclic compound and use thereof
CN114761412A (zh) 取代的大环化合物和相关治疗方法
CN117285547A (zh) 作为cftr的调节剂的大环化合物、其药物组合物、它们的用途和制备方法
CN110691784A (zh) 抑制mcl-1蛋白的化合物
CN114072407A (zh) 靶向prmt5的化合物
CN116670143A (zh) 囊性纤维化跨膜传导调控因子的调节剂
CN109195965A (zh) Wdr5蛋白质-蛋白质结合的抑制剂
CN106164076A (zh) 作为ROS1抑制剂的被取代的4，5，6，7‑四氢‑吡唑并[1，5‑a]吡嗪衍生物和5，6，7，8‑四氢‑4H‑吡唑并[1，5‑a][1，4]二氮杂环庚三烯衍生物
KR20200083515A (ko) 2고리 설폰 및 설폭사이드, 및 이의 사용 방법
WO2024149389A1 (zh) 取代桥环类抑制剂及其制备方法和应用
TW201615644A (zh) 作為人類免疫缺乏病毒複製之抑制劑的吡唑并嘧啶巨環化合物
EP3851436B1 (en) Novel heteroaromatic amide derivative and medicine containing same
CN114787167A (zh) 用于治疗寄生虫病的化合物及组合物
TW202527929A (zh) Ｃｄｋ２之可逆性離胺酸共價修飾劑及其用途
HK40020739A (en) N-heterocyclic compounds as orexin 2 agonists for the treatment of neurological disorders
HK40020739B (en) N-heterocyclic compounds as orexin 2 agonists for the treatment of neurological disorders
HK1234737A1 (en) Pyrazole amide derivative